Profile banner
Christopher Korban

Christopher Korban

Co-Founder & CEO, Revilico Inc., driving AI-driven drug discovery

chris_korban
Los Angeles, California
2.2K connections
Joined March 2026
Favicon imagelinkedin.com
Favicon imagerevilico.bio
Favicon imagescholar.google.com

Summary

Christopher Korban is a dedicated entrepreneur and CEO, co-founding Revilico Inc. in 2024. His company is focused on leveraging AI-driven computational tools to accelerate small molecule drug discovery, aiming to democratize access to these advanced technologies for a broad range of scientists. revilico+2
He is deeply involved in academic research in bioengineering and biomedical engineering, particularly at UCLA. His research includes work in the Wright Lab, Di Carlo Lab, and I2BL (Interdisciplinary Institute for Bioengineering and Life Science), contributing to fields like drug discovery, artificial intelligence, cancer therapeutic approaches, and drug delivery, as evidenced by multiple publications in 2024. affluense+3
Beyond his entrepreneurial and research pursuits, Christopher has held leadership positions in student and community organizations at UCLA, including President of Rieber Vista and Rieber Terrace, Vice President External Affairs of LSA, and Chief Financial Officer at College Communities Care, showcasing a commitment to community involvement and organizational management. affluense

Work

Education

Writing

Protein–polymer bioconjugation, immobilization, and encapsulation: a comparative review towards applicability, functionality, activity, and stability

January 1, 2024
Favicon imagescholar.google.com

Hybrid transformer and neural network configuration for protein classification using amino acids

January 1, 2024
Favicon imagescholar.google.com

An Analysis of Metabolic Conditions and Current Therapeutic Approaches: A Systematic Review

January 1, 2024
Favicon imagescholar.google.com

Potential Opportunities of Modeling Bioavailability for Monoclonal Antibodies: An Overview of mAbs and the current challenges of mAb development

January 1, 2024

This review article explores monoclonal antibodies (mAbs) and their pharmacodynamic (PD) and pharmacokinetic (PK) properties, using a machine learning model to assess bioavailability when delivered subcutaneously. It investigates drug optimization and patient outcomes when transitioning from traditional IV administrations to subcutaneous injections, extending a previous model with additional mAbs and dosage to create a more sophisticated model.

Favicon imagescholar.google.com

Revolutionizing Cancer Treatment-The Emergence and Impact of Antibody-Drug Conjugates (ADCs): A Systematic Review

January 1, 2024
Favicon imagescholar.google.com